APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Immunotherapy Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Cancer Immunotherapy Drugs Industry Research Report 2026

2 January 2026142 pages

Choose your research edition.

Industry ResearchCancer Immunotherapy Drugs Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Immunotherapy Drugs Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Cancer Immunotherapy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Immunotherapy Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Immunotherapy Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Cancer Immunotherapy Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Cancer Immunotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Cancer Immunotherapy Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Cancer Immunotherapy Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Cancer Immunotherapy Drugs include Takeda, Johnson & Johnson, Novartis, Merck KGaA, Roche, Eli Lilly, Pfizer, GSK and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Cancer Immunotherapy Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Cancer Immunotherapy Drugs Market by Company

Takeda

Johnson & Johnson

Novartis

Merck KGaA

Roche

Eli Lilly

Pfizer

GSK

Amgen

AbbVie

AstraZeneca

Seagen

Regeneron

Ono Pharmaceutical

Merck & Co

Innovent

Hengrui Medicine

Gilead Sciences

Exelixis

Bristol-Myers Squibb

Cancer Immunotherapy Drugs Segment by Type

CAR-T Cell Therapy

Cytokine-Based Immunotherapy

Immune Checkpoint Inhibitors

Other

Cancer Immunotherapy Drugs Segment by Application

Blood-related Cancer

Breast Cancer

Prostate Cancer

Lung Cancer

Other

Cancer Immunotherapy Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Cancer Immunotherapy Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Cancer Immunotherapy Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Cancer Immunotherapy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Cancer Immunotherapy Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Cancer Immunotherapy Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Cancer Immunotherapy Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Cancer Immunotherapy Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Cancer Immunotherapy Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Cancer Immunotherapy Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Cancer Immunotherapy Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Cancer Immunotherapy Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Cancer Immunotherapy Drugs, Product Type & Application Table 14. Global Cancer Immunotherapy Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Cancer Immunotherapy Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Takeda Company Information Table 19. Takeda Business Overview Table 20. Takeda Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Takeda Cancer Immunotherapy Drugs Product Portfolio Table 22. Takeda Recent Developments Table 23. Johnson & Johnson Company Information Table 24. Johnson & Johnson Business Overview Table 25. Johnson & Johnson Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Johnson & Johnson Cancer Immunotherapy Drugs Product Portfolio Table 27. Johnson & Johnson Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Novartis Cancer Immunotherapy Drugs Product Portfolio Table 32. Novartis Recent Developments Table 33. Merck KGaA Company Information Table 34. Merck KGaA Business Overview Table 35. Merck KGaA Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Merck KGaA Cancer Immunotherapy Drugs Product Portfolio Table 37. Merck KGaA Recent Developments Table 38. Roche Company Information Table 39. Roche Business Overview Table 40. Roche Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Roche Cancer Immunotherapy Drugs Product Portfolio Table 42. Roche Recent Developments Table 43. Eli Lilly Company Information Table 44. Eli Lilly Business Overview Table 45. Eli Lilly Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Eli Lilly Cancer Immunotherapy Drugs Product Portfolio Table 47. Eli Lilly Recent Developments Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Pfizer Cancer Immunotherapy Drugs Product Portfolio Table 52. Pfizer Recent Developments Table 53. GSK Company Information Table 54. GSK Business Overview Table 55. GSK Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. GSK Cancer Immunotherapy Drugs Product Portfolio Table 57. GSK Recent Developments Table 58. Amgen Company Information Table 59. Amgen Business Overview Table 60. Amgen Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Amgen Cancer Immunotherapy Drugs Product Portfolio Table 62. Amgen Recent Developments Table 63. AbbVie Company Information Table 64. AbbVie Business Overview Table 65. AbbVie Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. AbbVie Cancer Immunotherapy Drugs Product Portfolio Table 67. AbbVie Recent Developments Table 68. AstraZeneca Company Information Table 69. AstraZeneca Business Overview Table 70. AstraZeneca Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. AstraZeneca Cancer Immunotherapy Drugs Product Portfolio Table 72. AstraZeneca Recent Developments Table 73. Seagen Company Information Table 74. Seagen Business Overview Table 75. Seagen Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Seagen Cancer Immunotherapy Drugs Product Portfolio Table 77. Seagen Recent Developments Table 78. Regeneron Company Information Table 79. Regeneron Business Overview Table 80. Regeneron Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Regeneron Cancer Immunotherapy Drugs Product Portfolio Table 82. Regeneron Recent Developments Table 83. Ono Pharmaceutical Company Information Table 84. Ono Pharmaceutical Business Overview Table 85. Ono Pharmaceutical Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Ono Pharmaceutical Cancer Immunotherapy Drugs Product Portfolio Table 87. Ono Pharmaceutical Recent Developments Table 88. Merck & Co Company Information Table 89. Merck & Co Business Overview Table 90. Merck & Co Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Merck & Co Cancer Immunotherapy Drugs Product Portfolio Table 92. Merck & Co Recent Developments Table 93. Innovent Company Information Table 94. Innovent Business Overview Table 95. Innovent Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Innovent Cancer Immunotherapy Drugs Product Portfolio Table 97. Innovent Recent Developments Table 98. Hengrui Medicine Company Information Table 99. Hengrui Medicine Business Overview Table 100. Hengrui Medicine Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Hengrui Medicine Cancer Immunotherapy Drugs Product Portfolio Table 102. Hengrui Medicine Recent Developments Table 103. Gilead Sciences Company Information Table 104. Gilead Sciences Business Overview Table 105. Gilead Sciences Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Gilead Sciences Cancer Immunotherapy Drugs Product Portfolio Table 107. Gilead Sciences Recent Developments Table 108. Exelixis Company Information Table 109. Exelixis Business Overview Table 110. Exelixis Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Exelixis Cancer Immunotherapy Drugs Product Portfolio Table 112. Exelixis Recent Developments Table 113. Bristol-Myers Squibb Company Information Table 114. Bristol-Myers Squibb Business Overview Table 115. Bristol-Myers Squibb Cancer Immunotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Bristol-Myers Squibb Cancer Immunotherapy Drugs Product Portfolio Table 117. Bristol-Myers Squibb Recent Developments Table 118. Global Cancer Immunotherapy Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 119. Global Cancer Immunotherapy Drugs Sales by Region (2021-2026) & (K Units) Table 120. Global Cancer Immunotherapy Drugs Sales Market Share by Region (2021-2026) Table 121. Global Cancer Immunotherapy Drugs Sales by Region (2027-2032) & (K Units) Table 122. Global Cancer Immunotherapy Drugs Sales Market Share by Region (2027-2032) Table 123. Global Cancer Immunotherapy Drugs Revenue by Region (2021-2026) & (US$ Million) Table 124. Global Cancer Immunotherapy Drugs Revenue Market Share by Region (2021-2026) Table 125. Global Cancer Immunotherapy Drugs Revenue by Region (2027-2032) & (US$ Million) Table 126. Global Cancer Immunotherapy Drugs Revenue Market Share by Region (2027-2032) Table 127. North America Cancer Immunotherapy Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. North America Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 129. North America Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 130. North America Cancer Immunotherapy Drugs Revenue by Country (2021-2026) & (US$ Million) Table 131. North America Cancer Immunotherapy Drugs Revenue by Country (2027-2032) & (US$ Million) Table 132. Europe Cancer Immunotherapy Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Europe Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 134. Europe Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 135. Europe Cancer Immunotherapy Drugs Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe Cancer Immunotherapy Drugs Revenue by Country (2027-2032) & (US$ Million) Table 137. Asia Pacific Cancer Immunotherapy Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Asia Pacific Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 139. Asia Pacific Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 140. Asia Pacific Cancer Immunotherapy Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. Asia Pacific Cancer Immunotherapy Drugs Revenue by Country (2027-2032) & (US$ Million) Table 142. South America Cancer Immunotherapy Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. South America Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 144. South America Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 145. South America Cancer Immunotherapy Drugs Revenue by Country (2021-2026) & (US$ Million) Table 146. South America Cancer Immunotherapy Drugs Revenue by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa Cancer Immunotherapy Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Middle East and Africa Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 149. Middle East and Africa Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 150. Middle East and Africa Cancer Immunotherapy Drugs Revenue by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa Cancer Immunotherapy Drugs Revenue by Country (2027-2032) & (US$ Million) Table 152. Global Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 153. Global Cancer Immunotherapy Drugs Sales by Type (2027-2032) & (K Units) Table 154. Global Cancer Immunotherapy Drugs Sales Market Share by Type (2021-2026) Table 155. Global Cancer Immunotherapy Drugs Sales Market Share by Type (2027-2032) Table 156. Global Cancer Immunotherapy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 157. Global Cancer Immunotherapy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 158. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2021-2026) Table 159. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2027-2032) Table 160. Global Cancer Immunotherapy Drugs Price by Type (2021-2026) & (US$/Unit) Table 161. Global Cancer Immunotherapy Drugs Price by Type (2027-2032) & (US$/Unit) Table 162. Global Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 163. Global Cancer Immunotherapy Drugs Sales by Application (2027-2032) & (K Units) Table 164. Global Cancer Immunotherapy Drugs Sales Market Share by Application (2021-2026) Table 165. Global Cancer Immunotherapy Drugs Sales Market Share by Application (2027-2032) Table 166. Global Cancer Immunotherapy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 167. Global Cancer Immunotherapy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 168. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2021-2026) Table 169. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2027-2032) Table 170. Global Cancer Immunotherapy Drugs Price by Application (2021-2026) & (US$/Unit) Table 171. Global Cancer Immunotherapy Drugs Price by Application (2027-2032) & (US$/Unit) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Cancer Immunotherapy Drugs Distributors List Table 175. Cancer Immunotherapy Drugs Customers List Table 176. Cancer Immunotherapy Drugs Industry Trends Table 177. Cancer Immunotherapy Drugs Industry Drivers Table 178. Cancer Immunotherapy Drugs Industry Restraints Table 179. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Cancer Immunotherapy Drugs Product Image Figure 5. Global Cancer Immunotherapy Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Cancer Immunotherapy Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Cancer Immunotherapy Drugs Sales (2021-2032) & (K Units) Figure 8. Global Cancer Immunotherapy Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. CAR-T Cell Therapy Product Image Figure 10. Cytokine-Based Immunotherapy Product Image Figure 11. Immune Checkpoint Inhibitors Product Image Figure 12. Other Product Image Figure 13. Blood-related Cancer Product Image Figure 14. Breast Cancer Product Image Figure 15. Prostate Cancer Product Image Figure 16. Lung Cancer Product Image Figure 17. Other Product Image Figure 18. Global Cancer Immunotherapy Drugs Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Cancer Immunotherapy Drugs, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Cancer Immunotherapy Drugs Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Cancer Immunotherapy Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Cancer Immunotherapy Drugs Sales by Region in 2025 Figure 24. Global Cancer Immunotherapy Drugs Revenue by Region in 2025 Figure 25. North America Cancer Immunotherapy Drugs Market Size by Country in 2025 Figure 26. North America Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032) Figure 27. North America Cancer Immunotherapy Drugs Revenue Market Share by Country (2021-2032) Figure 28. United States Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Cancer Immunotherapy Drugs Market Size by Country in 2025 Figure 31. Europe Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032) Figure 32. Europe Cancer Immunotherapy Drugs Revenue Market Share by Country (2021-2032) Figure 33. Germany Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Nordic Countries Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Asia Pacific Cancer Immunotherapy Drugs Market Size by Country in 2025 Figure 40. Asia Pacific Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032) Figure 41. Asia Pacific Cancer Immunotherapy Drugs Revenue Market Share by Country (2021-2032) Figure 42. China Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Japan Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South Korea Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. India Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Australia Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. China Taiwan Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South America Cancer Immunotherapy Drugs Market Size by Country in 2025 Figure 51. South America Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032) Figure 52. South America Cancer Immunotherapy Drugs Revenue Market Share by Country (2021-2032) Figure 53. Mexico Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Brazil Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa Cancer Immunotherapy Drugs Market Size by Country in 2025 Figure 57. Middle East and Africa Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa Cancer Immunotherapy Drugs Revenue Market Share by Country (2021-2032) Figure 59. Turkey Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. UAE Cancer Immunotherapy Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Global Cancer Immunotherapy Drugs Sales Market Share by Type (2021-2032) Figure 63. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2021-2032) Figure 64. Global Cancer Immunotherapy Drugs Price (US$/Unit) by Type (2021-2032) Figure 65. Global Cancer Immunotherapy Drugs Sales Market Share by Application (2021-2032) Figure 66. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2021-2032) Figure 67. Global Cancer Immunotherapy Drugs Price (US$/Unit) by Application (2021-2032) Figure 68. Cancer Immunotherapy Drugs Value Chain Figure 69. Cancer Immunotherapy Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Cancer Immunotherapy Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • CAR-T Cell Therapy
  • Cytokine-Based Immunotherapy
  • Immune Checkpoint Inhibitors
  • Other
Applications
  • Blood-related Cancer
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Other
Companies covered
  • Takeda
  • Johnson & Johnson
  • Novartis
  • Merck KGaA
  • Roche
  • Eli Lilly
  • Pfizer
  • GSK
  • Amgen
  • AbbVie
  • AstraZeneca
  • Seagen
  • Regeneron
  • Ono Pharmaceutical
  • Merck & Co
  • Innovent
  • Hengrui Medicine
  • Gilead Sciences
  • Exelixis
  • Bristol-Myers Squibb

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Cancer Immunotherapy Drugs Market Size (2021-2032)
  4. 2.2.2 Global Cancer Immunotherapy Drugs Sales (2021-2032)
  5. 2.2.3 Global Cancer Immunotherapy Drugs Market Average Price (2021-2032)
  6. 2.3 Cancer Immunotherapy Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 CAR-T Cell Therapy
  9. 2.3.3 Cytokine-Based Immunotherapy
  10. 2.3.4 Immune Checkpoint Inhibitors
  11. 2.3.5 Other
  12. 2.4 Cancer Immunotherapy Drugs by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Blood-related Cancer
  15. 2.4.3 Breast Cancer
  16. 2.4.4 Prostate Cancer
  17. 2.4.5 Lung Cancer
  18. 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Cancer Immunotherapy Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Cancer Immunotherapy Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Cancer Immunotherapy Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Cancer Immunotherapy Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Cancer Immunotherapy Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Cancer Immunotherapy Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Cancer Immunotherapy Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Cancer Immunotherapy Drugs, Established Date
  9. 3.9 Global Cancer Immunotherapy Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Takeda
  2. 4.1.1 Takeda Company Information
  3. 4.1.2 Takeda Business Overview
  4. 4.1.3 Takeda Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Takeda Cancer Immunotherapy Drugs Product Portfolio
  6. 4.1.5 Takeda Recent Developments
  7. 4.2 Johnson & Johnson
  8. 4.2.1 Johnson & Johnson Company Information
  9. 4.2.2 Johnson & Johnson Business Overview
  10. 4.2.3 Johnson & Johnson Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Johnson & Johnson Cancer Immunotherapy Drugs Product Portfolio
  12. 4.2.5 Johnson & Johnson Recent Developments
  13. 4.3 Novartis
  14. 4.3.1 Novartis Company Information
  15. 4.3.2 Novartis Business Overview
  16. 4.3.3 Novartis Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis Cancer Immunotherapy Drugs Product Portfolio
  18. 4.3.5 Novartis Recent Developments
  19. 4.4 Merck KGaA
  20. 4.4.1 Merck KGaA Company Information
  21. 4.4.2 Merck KGaA Business Overview
  22. 4.4.3 Merck KGaA Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Merck KGaA Cancer Immunotherapy Drugs Product Portfolio
  24. 4.4.5 Merck KGaA Recent Developments
  25. 4.5 Roche
  26. 4.5.1 Roche Company Information
  27. 4.5.2 Roche Business Overview
  28. 4.5.3 Roche Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Roche Cancer Immunotherapy Drugs Product Portfolio
  30. 4.5.5 Roche Recent Developments
  31. 4.6 Eli Lilly
  32. 4.6.1 Eli Lilly Company Information
  33. 4.6.2 Eli Lilly Business Overview
  34. 4.6.3 Eli Lilly Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Eli Lilly Cancer Immunotherapy Drugs Product Portfolio
  36. 4.6.5 Eli Lilly Recent Developments
  37. 4.7 Pfizer
  38. 4.7.1 Pfizer Company Information
  39. 4.7.2 Pfizer Business Overview
  40. 4.7.3 Pfizer Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer Cancer Immunotherapy Drugs Product Portfolio
  42. 4.7.5 Pfizer Recent Developments
  43. 4.8 GSK
  44. 4.8.1 GSK Company Information
  45. 4.8.2 GSK Business Overview
  46. 4.8.3 GSK Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 GSK Cancer Immunotherapy Drugs Product Portfolio
  48. 4.8.5 GSK Recent Developments
  49. 4.9 Amgen
  50. 4.9.1 Amgen Company Information
  51. 4.9.2 Amgen Business Overview
  52. 4.9.3 Amgen Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Amgen Cancer Immunotherapy Drugs Product Portfolio
  54. 4.9.5 Amgen Recent Developments
  55. 4.10 AbbVie
  56. 4.10.1 AbbVie Company Information
  57. 4.10.2 AbbVie Business Overview
  58. 4.10.3 AbbVie Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 AbbVie Cancer Immunotherapy Drugs Product Portfolio
  60. 4.10.5 AbbVie Recent Developments
  61. 4.11 AstraZeneca
  62. 4.11.1 AstraZeneca Company Information
  63. 4.11.2 AstraZeneca Business Overview
  64. 4.11.3 AstraZeneca Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 AstraZeneca Cancer Immunotherapy Drugs Product Portfolio
  66. 4.11.5 AstraZeneca Recent Developments
  67. 4.12 Seagen
  68. 4.12.1 Seagen Company Information
  69. 4.12.2 Seagen Business Overview
  70. 4.12.3 Seagen Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Seagen Cancer Immunotherapy Drugs Product Portfolio
  72. 4.12.5 Seagen Recent Developments
  73. 4.13 Regeneron
  74. 4.13.1 Regeneron Company Information
  75. 4.13.2 Regeneron Business Overview
  76. 4.13.3 Regeneron Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Regeneron Cancer Immunotherapy Drugs Product Portfolio
  78. 4.13.5 Regeneron Recent Developments
  79. 4.14 Ono Pharmaceutical
  80. 4.14.1 Ono Pharmaceutical Company Information
  81. 4.14.2 Ono Pharmaceutical Business Overview
  82. 4.14.3 Ono Pharmaceutical Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Ono Pharmaceutical Cancer Immunotherapy Drugs Product Portfolio
  84. 4.14.5 Ono Pharmaceutical Recent Developments
  85. 4.15 Merck & Co
  86. 4.15.1 Merck & Co Company Information
  87. 4.15.2 Merck & Co Business Overview
  88. 4.15.3 Merck & Co Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Merck & Co Cancer Immunotherapy Drugs Product Portfolio
  90. 4.15.5 Merck & Co Recent Developments
  91. 4.16 Innovent
  92. 4.16.1 Innovent Company Information
  93. 4.16.2 Innovent Business Overview
  94. 4.16.3 Innovent Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Innovent Cancer Immunotherapy Drugs Product Portfolio
  96. 4.16.5 Innovent Recent Developments
  97. 4.17 Hengrui Medicine
  98. 4.17.1 Hengrui Medicine Company Information
  99. 4.17.2 Hengrui Medicine Business Overview
  100. 4.17.3 Hengrui Medicine Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Hengrui Medicine Cancer Immunotherapy Drugs Product Portfolio
  102. 4.17.5 Hengrui Medicine Recent Developments
  103. 4.18 Gilead Sciences
  104. 4.18.1 Gilead Sciences Company Information
  105. 4.18.2 Gilead Sciences Business Overview
  106. 4.18.3 Gilead Sciences Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Gilead Sciences Cancer Immunotherapy Drugs Product Portfolio
  108. 4.18.5 Gilead Sciences Recent Developments
  109. 4.19 Exelixis
  110. 4.19.1 Exelixis Company Information
  111. 4.19.2 Exelixis Business Overview
  112. 4.19.3 Exelixis Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Exelixis Cancer Immunotherapy Drugs Product Portfolio
  114. 4.19.5 Exelixis Recent Developments
  115. 4.20 Bristol-Myers Squibb
  116. 4.20.1 Bristol-Myers Squibb Company Information
  117. 4.20.2 Bristol-Myers Squibb Business Overview
  118. 4.20.3 Bristol-Myers Squibb Cancer Immunotherapy Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Bristol-Myers Squibb Cancer Immunotherapy Drugs Product Portfolio
  120. 4.20.5 Bristol-Myers Squibb Recent Developments
5 Global Cancer Immunotherapy Drugs Market Scenario by Region
  1. 5.1 Global Cancer Immunotherapy Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Cancer Immunotherapy Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Cancer Immunotherapy Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Cancer Immunotherapy Drugs Sales by Region: 2027-2032
  5. 5.3 Global Cancer Immunotherapy Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Cancer Immunotherapy Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Cancer Immunotherapy Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Cancer Immunotherapy Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Cancer Immunotherapy Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Cancer Immunotherapy Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Cancer Immunotherapy Drugs Market Facts & Figures by Country
  15. 5.5.1 Europe Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Cancer Immunotherapy Drugs Sales by Country (2021-2032)
  17. 5.5.3 Europe Cancer Immunotherapy Drugs Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific Cancer Immunotherapy Drugs Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific Cancer Immunotherapy Drugs Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific Cancer Immunotherapy Drugs Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America Cancer Immunotherapy Drugs Market Facts & Figures by Country
  36. 5.7.1 South America Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America Cancer Immunotherapy Drugs Sales by Country (2021-2032)
  38. 5.7.3 South America Cancer Immunotherapy Drugs Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.8 Middle East and Africa Cancer Immunotherapy Drugs Market Facts & Figures by Country
  43. 5.8.1 Middle East and Africa Cancer Immunotherapy Drugs Market Size by Country: 2021 VS 2025 VS 2032
  44. 5.8.2 Middle East and Africa Cancer Immunotherapy Drugs Sales by Country (2021-2032)
  45. 5.8.3 Middle East and Africa Cancer Immunotherapy Drugs Revenue by Country (2021-2032)
  46. 5.8.4 Turkey
  47. 5.8.5 Saudi Arabia
  48. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Cancer Immunotherapy Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Cancer Immunotherapy Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Cancer Immunotherapy Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Cancer Immunotherapy Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Cancer Immunotherapy Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Cancer Immunotherapy Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Cancer Immunotherapy Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Cancer Immunotherapy Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Cancer Immunotherapy Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Cancer Immunotherapy Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Cancer Immunotherapy Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Cancer Immunotherapy Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Cancer Immunotherapy Drugs Value Chain Analysis
  2. 8.1.1 Cancer Immunotherapy Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Cancer Immunotherapy Drugs Production Mode & Process
  5. 8.2 Cancer Immunotherapy Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Cancer Immunotherapy Drugs Distributors
  8. 8.2.3 Cancer Immunotherapy Drugs Customers
9 Global Cancer Immunotherapy Drugs Analyzing Market Dynamics
  1. 9.1 Cancer Immunotherapy Drugs Industry Trends
  2. 9.2 Cancer Immunotherapy Drugs Industry Drivers
  3. 9.3 Cancer Immunotherapy Drugs Industry Opportunities and Challenges
  4. 9.4 Cancer Immunotherapy Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst